Top Page
ValiRx plc
(LSE:VAL)
ValiRx plc (VAL) vs. iShares MSCI United Kingdom ETF (EWC)
ValiRx plc Business Overview & Revenue Model
ValiRx plc Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 49.77K | 9.60K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -217.22K | -246.04K | -224.27K | -228.79K | -229.50K |
| EBITDA | -1.86M | -2.04M | -2.37M | -1.45M | -1.31M |
| Net Income | -1.92M | -2.04M | -2.41M | -1.55M | -1.47M |
Balance Sheet | |||||
| Total Assets | 4.26M | 3.13M | 3.98M | 3.52M | 4.94M |
| Cash, Cash Equivalents and Short-Term Investments | 1.56M | 174.68K | 1.14M | 593.67K | 1.85M |
| Total Debt | 11.86K | 22.07K | 37.71K | 58.72K | 71.06K |
| Total Liabilities | 346.41K | 226.51K | 149.65K | 109.56K | 182.40K |
| Stockholders Equity | 4.32M | 3.22M | 4.05M | 3.60M | 4.91M |
Cash Flow | |||||
| Free Cash Flow | -1.62M | -2.08M | -1.71M | -1.26M | -2.00M |
| Operating Cash Flow | -1.58M | -1.77M | -1.71M | -1.26M | -1.91M |
| Investing Cash Flow | -38.16K | -306.18K | 0.00 | 0.00 | -91.29K |
| Financing Cash Flow | 3.00M | 1.12M | 2.26M | 7.34K | 3.85M |
ValiRx plc Technical Analysis
ValiRx plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | £4.51M | ― | -46.72% | ― | -100.00% | 68.42% | |
| ― | £6.59M | -0.75 | -153.80% | ― | ― | -633.33% | |
| ― | £14.49M | ― | -139.16% | ― | 72.98% | 55.36% | |
| ― | £6.36M | -0.11 | -333.59% | ― | 45.22% | 55.71% | |
| ― | £935.87K | -0.17 | ― | ― | 418.49% | 27.86% |
ValiRx plc Corporate Events
ValiRx Plc has announced a retail offer via the Winterflood Retail Access Platform to raise up to £300,000 through the issuance of new ordinary shares and warrants. This initiative is part of a broader fundraising effort, where the company has conditionally raised £750,000 through a placing and subscription of new shares. The funds raised will support the company’s ongoing projects and operations. The offer is open to eligible retail investors in the UK and is expected to close on 3 November 2025, with the results announced shortly thereafter. This move aims to strengthen ValiRx’s financial position and expand its retail shareholder base.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
ValiRx PLC has announced a fundraising initiative to raise up to £1,050,000 through a combination of firm and conditional placings, a WRAP Retail Offer, and direct subscriptions by company directors. The initiative, which includes the issuance of new shares and fundraising warrants, aims to support the company’s operations in a challenging funding environment. The funds will be used to expand ValiRx’s evaluation pipeline and progress existing projects, enhancing its strategic position in the oncology and women’s health sectors.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
ValiRx PLC announced significant progress in its subsidiary Inaphaea Limited, including the completion of a service contract phase with Amply Discovery Limited and a substantial UKRI grant for developing an in-silico spheroid modeling platform. These advancements, alongside collaborations with Nottingham Health Trust and TwinEdge BioScience, enhance ValiRx’s capabilities in drug development and patient-derived cell modeling. Additionally, ValiRx’s agreement with Apis Assay Technologies Ltd to evaluate HER2 targeting technology and recent academic appointments for key personnel underscore the company’s commitment to innovation and collaboration in cancer therapeutics.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
ValiRx Plc has released its unaudited half-yearly report for the period ending June 30, 2025, highlighting strategic and operational advancements, including new partnerships and agreements aimed at enhancing its cancer therapeutic development. The company has undergone a strategic review to improve operational efficiency, resulting in cost savings and a leaner team structure. Despite challenging trading conditions and funding uncertainties, ValiRx has secured multiple pump-priming awards and is exploring further grant opportunities. The company is also focusing on developing its Inaphaea Biolabs subsidiary and enhancing its capabilities in new approach methodologies, aligning with regulatory trends to phase out animal testing.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
ValiRx’s subsidiary, Inaphaea Limited, has entered a collaboration with TwinEdge Bioscience to enhance cancer therapy development through digital ‘patient avatars,’ leveraging AI and computational biology. This partnership aims to transform drug development by creating one of the largest populations of digital twins, potentially reducing clinical trial costs and improving patient-drug matching. Inaphaea also advances its capabilities with agreements for new cancer cell models and the 3K Screen program, which identified promising drug candidates for further testing and commercial opportunities.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
ValiRx PLC’s subsidiary, Cytolytix Limited, has received a notice of allowance for a key European patent application related to its nanoparticle technology for anti-cancer peptides, strengthening its intellectual property portfolio. The company is advancing its second-generation delivery platform and collaborating with partners to evaluate its efficacy in cancer models, including triple negative breast cancer and prostate cancer, with promising preliminary results. These developments are expected to enhance ValiRx’s positioning in the oncolytic peptide space and provide opportunities for partnerships and funding.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
ValiRx PLC has established a new subsidiary, Blue Ribbon Bio Limited, to manage its prostate cancer assets, including the intellectual property for Val201. The company plans to file new patents for Val201 and expedite its development for prostate cancer treatment. Additionally, ValiRx has received a notice of allowance for a Canadian patent for the Val201 peptide’s use in treating endometriosis. This strategic move aims to enhance the company’s portfolio in prostate cancer and women’s health, potentially attracting partners for clinical development and addressing unmet needs in cancer treatment.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
ValiRx PLC, through its subsidiary Inaphaea BioLabs, has been awarded a Knowledge Transfer Voucher from The Open University to enhance its research capabilities in cancer therapeutics. This collaboration will focus on advanced imaging and machine learning techniques to improve drug response assessments in tumor models, aligning with recent regulatory changes that favor 3D cell cultures over animal testing. This initiative is expected to strengthen ValiRx’s technical capabilities and foster future collaborations, potentially accelerating the development of therapeutic candidates.
ValiRx announced an update on its Evaluation Agreement with Stingray Bio, initially aimed at developing novel cancer therapeutics. The initial evaluation did not meet the criteria for licensing, leading to a new agreement focusing on in-silico and in-vitro optimization of Stingray’s drug compounds. ValiRx will fund the work, with an option to license the technology into a jointly owned Special Purpose Vehicle. This approach allows ValiRx to de-risk early-stage innovation and retain potential upside, while also enabling Stingray to seek additional funding, potentially accelerating the transition to clinical development.
ValiRx Plc, through its subsidiary Inaphaea BioLabs, has entered into an exclusive licensing agreement with Dominion Biotech Ltd for its PredictRx® platform, a personalized cancer screening service. This agreement, which allows Inaphaea to receive a 50% share of global net revenues, is strategically significant for demonstrating the commercial application of ValiRx’s platform and establishing future buyout value, potentially enhancing the company’s industry positioning in precision oncology.